Sorry - horrible pun.
Eisai Ltd, Pfizer UK and Shire Pharmaceuticals have lodged an appeal against the National Institute for Health and Clinical Excellence's (NICE) continuing proposal to deny patients with mild forms of Alzheimer's disease treatment with anti-dementia drugs on the UK National Health Service (NHS).
NICE's stance on anti-cholinesterase drugs - which are not used to treat the disease itself but help to alleviate some of its symptoms - caused uproar in March last year when it first proposed that their use is not cost-effective under the NHS, as they do not benefit all patients.
Products in the firing line include: Aricept (donepezil), marketed by Eisai and its partner Pfizer; Shire's Reminyl (galantamine); Novartis' Exelon (rivastigmine); and Lundbeck's Ebixa (memantine).
More here.
No comments:
Post a Comment